Researchers Explore Engineered Bacteria as a Potential Future Cancer Treatment
Scientists are investigating a promising new approach to cancer treatment that involves using specially engineered bacteria to target and grow inside solid tumors.
A research team led by the University of Waterloo is developing a method that uses modified bacteria to reach areas within tumors that are difficult for conventional treatments to access. The work remains in the research and pre-clinical stage and is aimed at improving future cancer therapies.
The study focuses on Clostridium sporogenes, a naturally occurring soil bacterium that thrives in environments with little or no oxygen. Researchers say this characteristic makes it particularly suitable for targeting the inner regions of solid tumors, where oxygen levels are often extremely low.
According to Dr. Marc Aucoin, a professor of chemical engineering at the University of Waterloo, bacterial spores can enter these low-oxygen areas and begin growing in conditions that support their survival.
Scientists believe this process may help target tumor tissue from within, offering a potential complementary approach to existing cancer treatments.
One challenge identified by researchers is that the bacterium has difficulty surviving near the outer regions of tumors, where small amounts of oxygen are present. To address this issue, the team introduced a gene from a related bacterium known for greater oxygen tolerance.
The modification is designed to help the bacteria remain active in slightly oxygenated areas while still concentrating their activity within the tumor environment.
Researchers also developed a control mechanism to ensure that the oxygen-tolerance feature activates only under specific conditions. This is intended to improve safety by limiting bacterial activity outside the target area.
To achieve this, the team utilized a natural bacterial communication process known as quorum sensing. Through this system, bacteria can detect when enough of their population has accumulated and then activate specific genetic functions.
In laboratory studies, researchers successfully demonstrated both improved oxygen tolerance and the ability to control gene activation using quorum sensing technology.
The next phase of the project will involve combining these features into a single bacterial strain and evaluating its performance in pre-clinical tumor studies.
While the research is still in its early stages, scientists say it highlights the growing potential of biotechnology and synthetic biology in developing innovative approaches for future cancer treatment.
